Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Starting soon · Phase 1/Phase 2

Conditions studied: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer

In brief

This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.

Key facts

Study ID

NCT07217990

Run by

Ohio State University Comprehensive Cancer Center

People needed

84

Starts

2026-09-15

Expected to finish

2027-12-31

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged 18 years or older
• Early-stage breast cancer diagnosis (cT1-3 N0 or cT1-2 N1) and a Human Epidermal Receptor 2 (HER2)-positive or triple negative breast cancer (TNBC) tumor molecular subtype
• Planning to receive neoadjuvant chemotherapy (NAC) and radiation therapy (RT)

You may not qualify if…

• Pregnancy or lactation
• Inmate or prisoner
• Treatment with an investigational drug or other intervention throughout their breast cancer treatment
• Patients with skin involvement and/or distant metastases

Where it is running

• Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.